WGSNasdaqServices-Health ServicesFiscal year ends December 31
GeneDx Holdings Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$66.29+2.68 (+4.21%)
Close on Oct 19, 2026
- Market cap
- $1.97B
- P/E (TTM)
- –
- Dividend yield
- –
GeneDx Holdings Corp. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GeneDx Segment | $114.44M | – | – | – | $102.69M | – | – | – | – | – | – | – | 100.0% | +11.4% |
| Other | – | – | – | $2.05M | $908.00K | $0 | – | $252.00K | $1.59M | $961.00K | – | $2.95M | – | – |
| Gene Dx | – | $101.50M | $119.49M | $114.70M | $101.78M | $87.12M | $95.29M | $76.62M | $68.92M | $61.46M | $58.11M | $50.35M | – | – |
| Other | – | $758.00K | – | – | – | $0 | – | – | – | – | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostic test revenue: | $111.89M | $101.30M | $117.29M | $113.52M | $100.10M | $85.76M | $94.20M | $77.42M | $69.44M | $61.10M | $55.21M | $51.96M | 97.8% | +11.8% |
| Patients with third-party insurance | $94.73M | $84.92M | $101.05M | $95.02M | $81.10M | $68.06M | $79.27M | $59.54M | $52.05M | $43.84M | $42.81M | $35.78M | 82.8% | +16.8% |
| Institutional customers | $16.12M | $16.09M | $15.94M | $17.87M | $18.66M | $17.60M | $14.33M | $17.42M | $16.70M | $16.67M | $11.97M | $15.72M | 14.1% | -13.6% |
| Other revenue | $2.55M | $955.00K | $3.70M | $3.22M | $2.59M | $1.36M | $1.44M | -$544.00K | $1.08M | $1.32M | $2.20M | $1.35M | 2.2% | -1.5% |
| Self-pay patients | $1.04M | $286.00K | $297.00K | $629.00K | $339.00K | $96.00K | $600.00K | $460.00K | $692.00K | $591.00K | $431.00K | $460.00K | 0.9% | +207.4% |
By region
From the segment and revenue-disaggregation notes of GeneDx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.